ALPS LIFE SCIENCE INC. SET FOR NASDAQ LISTING FOLLOWING MERGER WITH GLOBALINK INVESTMENT

In a landmark development for Asia’s biotechnology sector, Alps Global Holding Berhad has announced a comprehensive combination with Globalink Investment Inc., positioning the integrated life sciences platform for major market expansion through a Nasdaq debut scheduled for Q2 2024.

Deal Valuation and Structure

The combined entity, to be named Alps Life Science Inc., carries an enterprise valuation of approximately US$1.6 billion. Under the definitive merger agreement finalized in late January 2024, all Alps shareholders will retain their equity positions in the newly formed company, gaining approximately 96.38% ownership stakes while Globalink’s existing stockholders will hold around 3.62%.

The transaction structure includes a performance-based component—Alps shareholders can receive up to 48 million additional shares contingent upon achieving specific revenue milestones over five fiscal years post-combination. These earnouts align shareholder interests with the company’s medium-term growth objectives.

Understanding Alps Global Holding Berhad

Operating since 2017, Alps Global Holding Berhad has evolved into a comprehensive platform bridging laboratory research, clinical services, and preventive wellness solutions. The Malaysian biotech enterprise specializes in precision medicine development utilizing advanced genomics DNA sequencing, mRNA technologies, and cellular therapy protocols.

The organization operates from strategically positioned facilities in Kuala Lumpur, including:

• Alps Medical Centre: Clinical service delivery
• Alps Wellness Centre: Patient wellness programs
• MyGenome: Bionexus-accredited molecular research institute with whole genome sequencing capabilities
• Celestialab: cGMP-certified cell manufacturing laboratory

Leadership Vision and Market Positioning

Dr. Tham Seng Kong, leading Alps as Chief Executive Officer, articulates the company’s regional ambition: advancing from competitive positioning toward collaborative frameworks that address emerging pandemic preparedness and preventative medicine needs across Asia-Pacific markets.

Say Leong Lim, Chief Executive Officer of Globalink Investment Inc., emphasized the strategic rationale: “The life sciences sector presents substantial opportunities. We recognize Alps’ potential to establish regional leadership in this high-growth domain.”

Capital Deployment and Strategic Objectives

The deal will generate net proceeds through Globalink’s trust account and concurrent PIPE financing to support operational expansion, capital investments, and general corporate development. The financial structure enables Alps to accelerate product commercialization, expand manufacturing capacity, and strengthen its integrated supply chain positioning.

Timeline and Regulatory Requirements

Closing is anticipated during Q2 2024, contingent upon stockholder approval from both entities and receipt of requisite regulatory authorizations. The prospective listing on Nasdaq represents a significant milestone for Malaysian biotechnology advancement into international capital markets.

Market Context

The proposed transaction reflects growing investor appetite for integrated life sciences platforms positioned at the convergence of diagnostics, therapeutics, and wellness innovation—particularly within Asia’s rapidly expanding healthcare infrastructure and aging populations seeking advanced treatment alternatives at competitive pricing structures.